Virtual Screening of Alkaloids and Flavonoids as Acetylcholinesterase and MAO-B Inhibitors by Molecular Docking and Dynamic Simulation Studies

References

• S. Przedborski, M. Vila, and V. Jackson, “Series Introduction: Neurodegeneration: What Is It and Where Are We?,” Journal of Clinical Investigation 111, no. 1 (2003): 3–10. doi:10.1172/JCI200317522.
   PubMed Web of Science ®Google Scholar
• B.N. Dugger, and D.W. Dickson, “Pathology of Neurodegenerative Diseases,” Cold Spring Harbor Perspectives in Biology 9, no. 7 (2017): a028035. doi:10.1101/cshperspect.a028035.
   PubMed Web of Science ®Google Scholar
• A.D. Gitler, P. Dhillon, and J. Shorter, “Neurodegenerative Disease: Models, Mechanisms, and a New Hope,” Disease Models & Mechanisms 10, no. 5 (2017): 499–502. doi:10.1242/dmm.030205.
   PubMed Web of Science ®Google Scholar
• Mehdi Sharifi-Rad, Chintha Lankatillake, Daniel A. Dias, Anca Oana Docea, Mohamad Fawzi Mahomoodally, Devina Lobine, Paul L. Chazot, Begum Kurt, Tugba Boyunegmez Tumer, Ana Catarina Moreira, et al., “Impact of Natural Compounds on Neurodegenerative Disorders: From Preclinical to Pharmacotherapeutics,” Journal of Clinical Medicine 9, no. 4 (2020): 1061. 1061. doi:10.3390/jcm9041061.
   PubMed Web of Science ®Google Scholar
• G.P. Kumar, and F. Khanum, “Neuroprotective Potential of Phytochemicals,” Pharmacognosy Reviews 6, no. 12 (2012): 81–90. doi:10.4103/0973-7847.99898.
   PubMedGoogle Scholar
• S. Bhambhani, R.K.R. Kondhare, and A.P. Giri, “Diversity in Chemical Structures and Biological Properties of Plant Alkaloids,” Molecules 26, no. 11 (2021): 3374. doi:10.3390/molecules26113374.
   PubMed Web of Science ®Google Scholar
• B. Noureddine, “Pharmacological Activity of Alkaloids: A Review,” Asian Journal of Botany 1, no. 1 (2018): 1–6.
   Google Scholar
• H. Ghulam, A. Rasul, H. Anwar, N. Aziz, A. Razzaq, W. Wei, M. Ali, J. Li, and X. Li, “Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders,” International Journal of Biological Sciences 14, no. 3 (2018): 341–57. doi:10.7150/ijbs.23247.
   PubMed Web of Science ®Google Scholar
• G. Shikha, A. Girdhar, S.K. Verma, V. Lather, and D. Pandita, “Plant Derived Alkaloids in Major Neurodegenerative Diseases: From Animal Models to Clinical Trials,” Journal of Ayurvedic and Herbal Medicine 1, no. 3 (2015): 91–100. doi:10.31254/jahm.2015.1307.
   Google Scholar
• M.R. Loizzo, R. Tundis, F. Menichini, and F. Menichini, “Natural Products and Their Derivatives as Cholinesterase Inhibitors in the Treatment of Neurodegenerative Disorders: An Update,” Current Medicinal Chemistry 15, no. 12 (2008): 1209–28. doi:10.2174/092986708784310422.
   PubMed Web of Science ®Google Scholar
• M. Pamela, “The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases,” International Journal of Molecular Sciences 20, no. 12 (2019): 3056.
   PubMed Web of Science ®Google Scholar
• S.L. Costa, V.D.A. Silva, C.S. Souza, C.C. Santos, I. Paris, P. Muñoz, and J. Segura-Aguilar, “Impact of Plant-Derived Flavonoids on Neurodegenerative Diseases,” Neurotoxicity Research 30, no. 1 (2016): 41–52. doi:10.1007/s12640-016-9600-1.
   PubMed Web of Science ®Google Scholar
• J.R. Frandsen, and P. Narayanasamy, “Neuroprotection through Flavonoid: Enhancement of the Glyoxalase Pathway,” Redox Biology 14 (2018): 465–73. doi:10.1016/j.redox.2017.10.015.
   PubMed Web of Science ®Google Scholar
• W. Shao-Hui, H. Yan-Lan, and L. Tong-Xiang, “Plant Distribution and Pharmacological Activity of Flavonoids,” Traditional Medicine Research 4 (2019): 269–87.
   Web of Science ®Google Scholar
• T.T. Cushnie, and A.J. Lamb, “Antimicrobial Activity of Flavonoids,” International Journal of Antimicrobial Agents 26, no. 5 (2005): 343–56. doi:10.1016/j.ijantimicag.2005.09.002.
   PubMed Web of Science ®Google Scholar
• A. Haake, K. Nguyen, L. Friedman, B. Chakkamparambil, and G.T. Grossberg, “An Update on the Utility and Safety of Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease,” Expert Opinion on Drug Safety 19, no. 2 (2020): 147–57. doi:10.1080/14740338.2020.1721456.
   PubMed Web of Science ®Google Scholar
• M. Bijo, D.G.T. Parambi, G.E. Mathew, M.S. Uddin, S.T. Inasu, H. Kim, A. Marathakam, M.K. Unnikrishnan, and S. Carradori, “Emerging Therapeutic Potentials of Dual‐Acting MAO and AChE Inhibitors in Alzheimer's and Parkinson's Diseases,” Archiv Der Pharmazie 352, no. 11 (2019): 1900177. doi:10.1002/ardp.201900177.
   Web of Science ®Google Scholar
• N. Makoto, and W. Maruyama, “Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders,” Current Pharmaceutical Design 16, no. 25 (2010): 2799–817.
   PubMed Web of Science ®Google Scholar
• P. Guglielmi, S. Carradori, G. Poli, D. Secci, R. Cirilli, G. Rotondi, P. Chimenti, A. Petzer, and J.P. Petzer, “Design, Synthesis, Docking Studies and Monoamine Oxidase Inhibition of a Small Library of 1-Acetyl-and 1-Thiocarbamoyl-3, 5-Diphenyl-4, 5-Dihydro-(1H)-Pyrazoles,” Molecules 24, no. 3 (2019): 484. doi:10.3390/molecules24030484.
   PubMed Web of Science ®Google Scholar
• J.P. James, D. Jyothi, and S. Priya, “In Silico Screening of Phytoconstituents with Antiviral Activities against SARS-COV-2 Main Protease, Nsp12 Polymerase, and Nsp13 Helicase Proteins,” Letters in Drug Design & Discovery 18, no. 8 (2021): 841–57. doi:10.2174/1570180818666210317162502.
   Web of Science ®Google Scholar
• D.D. Kodical, J.P. James, K. Deepthi, P. Kumar, C. Cyriac, and K.V. Gopika, “ADMET, Molecular Docking Studies and Binding Energy Calculations of Pyrimidine-2-Thiol Derivatives as Cox Inhibitors,” Research Journal of Pharmacy and Technology 13, no. 9 (2020): 4200–6. doi:10.5958/0974-360X.2020.00742.8.
   Google Scholar
• J.P. James, P. Kumar, A. Kumar, K.I. Bhat, and C.S. Shastry, “In Silico Anticancer Evaluation, Molecular Docking and Pharmacophore Modeling of Flavonoids against Various Cancer Targets,” Letters in Drug Design & Discovery 17, no. 12 (2020): 1485–501. doi:10.2174/1570180817999200730164222.
   Web of Science ®Google Scholar
• J.P. James, Apoorva, S.R. Monteiro, K.B. Sukesh, and A. Varun, “Design and Identification of Lead Compounds Targeting Nipah G Attachment Glycoprotein by In Silico Approaches,” Journal of Pharmaceutical Research International 33, no. 40A (2021): 156–69.
   Web of Science ®Google Scholar
• F.R. Makhouri, and J.B. Ghasemi, “In Silico Studies in Drug Research against Neurodegenerative Diseases,” Current Neuropharmacology 16, no. 6 (2018): 664–725. doi:10.2174/1570159X15666170823095628.
   PubMed Web of Science ®Google Scholar
• Y. Wang, C. Reis, R. Applegate, II, G. Stier, R. Martin, and J.H. Zhang, “Ischemic Conditioning-Induced Endogenous Brain Protection: Applications Pre-, Per-or Post-Stroke,” Experimental Neurology 272 (2015): 26–40. doi:10.1016/j.expneurol.2015.04.009.
   PubMed Web of Science ®Google Scholar
• Y.J. Liu, W. Peng, M.B. Hu, M. Xu, and C.J. Wu, “The Pharmacology, Toxicology and Potential Applications of Arecoline, a Review,” Pharmaceutical Biology 54, no. 11 (2016): 2753–60. doi:10.3109/13880209.2016.1160251.
   PubMed Web of Science ®Google Scholar
• K.S. Rangappa, “P1‐228: Muscarinic Receptor 1 Agonist Activity of Novel Arecoline Derivatives in Alzheimer's Dementia Models,” Alzheimer's & Dementia 5, no. 4S_Part_8 (2009): P243–P243. doi:10.1016/j.jalz.2009.04.235.
   Google Scholar
• A. Touqeer, M. Abdollahi, M. Daglia, S.F. Nabavi, and S.M. Nabavi, “Berberine and Neurodegeneration: A Review of Literature,” Pharmacological Reports 67, no. 5 (2015): 970–9.
   PubMed Web of Science ®Google Scholar
• Q. Siru, H. Tang, W. Li, Y. Gong, S. Li, J. Huang, and Y. Fang, “AMPK and Its Activator Berberine in the Treatment of Neurodegenerative Diseases,” Current Pharmaceutical Design 26, no. 39 (2020): 5054–66.
   PubMed Web of Science ®Google Scholar
• S.K. Anurag, S.K. Singh, M.K. Nandi, G. Mishra, A. Maurya, A. Rai, G.K. Rai, R. Awasthi, B. Sharma, and G.T. Kulkarni, “Berberine: A Plant-Derived Alkaloid with Therapeutic Potential to Combat Alzheimer’s Disease,” Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Central Nervous System Agents) 19, no. 3 (2019): 154–70.
   PubMedGoogle Scholar
• A.M. Lotfi, M.E. Rezvani, M. Khaksari, Z. Hafizi, Z. Pirmoradi, S. Niknazar, and F.Z. Mehrjerdi, “Neuroprotective Effect of Berberine Chloride on Cognitive Impairment and Hippocampal Damage in Experimental Model of Vascular Dementia,” Iranian Journal of Basic Medical Sciences 21, no. 1 (2018): 53.
   PubMed Web of Science ®Google Scholar
• M. Rivera-Oliver, and M. Diaz-Rios, “Using Caffeine and Other Adenosine Receptor Antagonists and Agonists as Therapeutic Tools against Neurodegenerative Diseases, a Review,” Life Sciences 101, no. 1-2 (2014): 1–9. doi:10.1016/j.lfs.2014.01.083.
   PubMed Web of Science ®Google Scholar
• D.M. Alexandre, and R.A. Cunha, “Therapeutic Opportunities for Caffeine in Alzheimer’s Disease and Other Neurodegenerative Disorders,” Journal of Alzheimer's Disease 20, no. 1 (2010): S1–S2.
   PubMedGoogle Scholar
• P. David, H. Hampel, and J. Pantel, “Galantamine for Alzheimer's Disease,” Expert Opinion on Drug Metabolism & Toxicology 6, no. 3 (2010): 345–54.
   PubMed Web of Science ®Google Scholar
• A.J. Queiroz, J.A. Lima, A.C. Pinto, R.B. De Alencastro, and M.G. Albuquerque, “Docking of the Alkaloid Geissospermine into Acetylcholinesterase: A Natural Scaffold Targeting the Treatment of Alzheimer’s Disease,” Journal of Molecular Modeling 17, no. 6 (2011): 1401–12.
   PubMed Web of Science ®Google Scholar
• H. Dandan, H. Wu, Y. Wei, W. Liu, F. Huang, H. Shi, B. Zhang, X. Wu, and C. Wang, “Effects of Harmine, an Acetylcholinesterase Inhibitor, on Spatial Learning and Memory of APP/PS1 Transgenic Mice and Scopolamine-Induced Memory Impairment Mice,” European Journal of Pharmacology 768 (2015): 96–107.
   PubMed Web of Science ®Google Scholar
• C. Bijaya, S. Prem, and S. Viral, “Neurodegenrative Disorders: Past, Present and Future,” International Journal of Applied Biology and Pharmaceutical Technology 5, no. 2 (2014): 14–28.
   Google Scholar
• M. Shinghung, W. Li, H. Fu, J. Luo, W. Cui, S. Hu, Y. Pang, P.R. Carlier, K.W. Tsim, R. Pi, et al., “Promising Tacrine/Huperzine a‐Based Dimeric Acetylcholinesterase Inhibitors for Neurodegenerative Disorders: From Relieving Symptoms to Modifying Diseases through Multitarget,” Journal of Neurochemistry 158, no. 6 (2021): 1381–93.
   PubMed Web of Science ®Google Scholar
• Q.Z. Ming, and Y. Ke, “Huperzine A: Is It an Effective Disease-Modifying Drug for Alzheimer’s Disease?,” Frontiers in Aging Neuroscience 6 (2014): 216.
   PubMed Web of Science ®Google Scholar
• Y.F. Xian, Q.Q. Mao, J.C. Wu, Z.R. Su, J.N. Chen, X.P. Lai, S.P. Ip, and Z.X. Lin, “Isorhynchophylline Treatment Improves the Amyloid-β-Induced Cognitive Impairment in Rats via Inhibition of Neuronal Apoptosis and Tau Protein Hyperphosphorylation,” Journal of Alzheimer's Disease 39, no. 2 (2014): 331–46. doi:10.3233/JAD-131457.
   PubMed Web of Science ®Google Scholar
• H.Q. Li, S.P. Ip, Q.J. Yuan, G.Q. Zheng, K.K. Tsim, T.T. Dong, G. Lin, Y. Han, Y. Liu, Y.F. Xian, et al., “Isorhynchophylline Ameliorates Cognitive Impairment via Modulating Amyloid Pathology, Tau Hyperphosphorylation and Neuroinflammation: Studies in a Transgenic Mouse Model of Alzheimer’s Disease,” Brain, Behavior, and Immunity 82 (2019): 264–78. doi:10.1016/j.bbi.2019.08.194.
   PubMed Web of Science ®Google Scholar
• J.J. Dimatelis, V.A. Russell, D.J. Stein, and W.M. Daniels, “The Effects of Lobeline and Naltrexone on Methamphetamine-Induced Place Preference and Striatal Dopamine and Serotonin Levels in Adolescent Rats with a History of Maternal Separation,” Metabolic Brain Disease 27, no. 3 (2012): 351–61. doi:10.1007/s11011-012-9288-8.
   PubMed Web of Science ®Google Scholar
• K. Jaskiran, P. Famta, M. Famta, M. Mehta, S. Satija, N. Sharma, M. Vyas, G.L. Khatik, D.K. Chellappan, and K. Dua, “Potential anti-Epileptic Phytoconstituents: An Updated Review,” Journal of Ethnopharmacology 268 (2021): 113565.
   PubMed Web of Science ®Google Scholar
• T. Pak, P. Cadet, K.J. Mantione, and G.B. Stefano, “Morphine via Nitric Oxide Modulates β-Amyloid Metabolism: A Novel Protective Mechanism for Alzheimer’s Disease,” Medical Science Monitor. 11, no. 10 (2005): 366.
   Web of Science ®Google Scholar
• R.A. Ribeiro, and J.R. Leite, “Nantenine Alkaloid Presents Anticonvulsant Effect on Two Classical Animal Models,” Phytomedicine 10, no. 6–7 (2003): 563–8. doi:10.1078/094471103322331557.
   PubMed Web of Science ®Google Scholar
• L.A. Jess, and F.J. Sanz, “Nicotine for Alzheimer's Disease,” Cochrane Database of Systematic Reviews 2 (2001): CD001749.
   Google Scholar
• M. Awanish, J.K. Punia, C. Bladen, G.W. Zamponi, and R.K. Goel, “Anticonvulsant Mechanisms of Piperine, a Piperidine Alkaloid,” Channels 9, no. 5 (2015): 317–23.
   PubMed Web of Science ®Google Scholar
• H. Lucian, J.A. Noumedem, O. Cioanca, M. Hancianu, V. Kuete, and M. Mihasan, “Methanolic Extract of Piper Nigrum Fruits Improves Memory Impairment by Decreasing Brain Oxidative Stress in Amyloid Beta (1–42) Rat Model of Alzheimer’s Disease,” Cellular and Molecular Neurobiology 34, no. 3 (2014): 437–49.
   PubMed Web of Science ®Google Scholar
• A. Baghdadi, B. Osamah, I.N. Prater, C.J. Schyf, and J. Werner, Geldenhuys, “Inhibition of Monoamine Oxidase by Derivatives of Piperine, an Alkaloid from the Pepper Plant Piper nigrum, for Possible Use in Parkinson’s Disease,” Bioorganic & Medicinal Chemistry Letters 22, no. 23 (2012): 7183–8. doi:10.1016/j.bmcl.2012.09.056.
   PubMed Web of Science ®Google Scholar
• I.E. Orhan, and F.S. Senol, “Alkaloids and Inhibitory Effects against Enzymes Linked to Neurodegenerative Diseases (Physostigmine, Galanthamine, Huperzine, Etc.),” in Natural Products, edited by K. Ramawat and J. M. Mérillon (Berlin, Heidelberg: Springer).
   Google Scholar
• W. Philip, A. Sorribas, and M.J.R. Howes, “Natural Products as a Source of Alzheimer's Drug Leads,” Natural Product Reports 28, no. 1 (2011): 48–77.
   PubMed Web of Science ®Google Scholar
• H. Wang, K. Zhang, L. Zhao, J. Tang, L. Gao, and Z. Wei, “Anti-Inflammatory Effects of Vinpocetine on the Functional Expression of Nuclear Factor-Kappa B and Tumor Necrosis Factor-Alpha in a Rat Model of Cerebral Ischemia-Reperfusion Injury,” Neuroscience Letters 566 (2014): 247–51. doi:10.1016/j.neulet.2014.02.045.
   PubMed Web of Science ®Google Scholar
• N.S. Fazel, H. Khan, G. D'onofrio, D. Samec, S. Shirooie, A.R. Dehpour, S. Arguelles, S. Habtemariam, and E.S. Sanchez, “Apigenin as Neuroprotective Agent: Of Mice and Men,” Pharmacological Research 128 (2018): 359–65.
   PubMed Web of Science ®Google Scholar
• L. Yanwei, J. Zhao, and C. Holscher, “Therapeutic Potential of Baicalein in Alzheimer’s Disease and Parkinson’s Disease,” CNS Drugs 31, no. 8 (2017): 639–52.
   PubMed Web of Science ®Google Scholar
• M.B. Khan, M.M. Khan, A. Khan, M.E. Ahmed, T. Ishrat, R. Tabassum, K. Vaibhav, A. Ahmad, and F. Islam, “Naringenin Ameliorates Alzheimer’s Disease (AD)-Type Neurodegeneration with Cognitive Impairment (AD-TNDCI) Caused by the Intracerebroventricular-Streptozotocin in Rat Model,” Neurochemistry International 61, no. 7 (2012): 1081–93. doi:10.1016/j.neuint.2012.07.025.
   PubMed Web of Science ®Google Scholar
• D.M. Wang, Y.J. Yang, L. Zhang, X. Zhang, F.F. Guan, and L.F. Zhang, “Naringin Enhances CaMKII Activity and Improves Long-Term Memory in a Mouse Model of Alzheimer’s Disease,” International Journal of Molecular Sciences 14, no. 3 (2013): 5576–86. doi:10.3390/ijms14035576.
   PubMed Web of Science ®Google Scholar
• H. Ullah, and H. Khan, “Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing,” Frontiers in Pharmacology 9 (2018): 422. doi:10.3389/fphar.2018.00422.
   PubMed Web of Science ®Google Scholar
• B. Budzynska, C. Faggio, M. Kruk-Slomka, D. Samec, S.F. Nabavi, A. Sureda, K.P. Devi, and S.M. Nabavi, “Rutin as Neuroprotective Agent: From Bench to Bedside,” Current Medicinal Chemistry 26, no. 27 (2019): 5152–64. doi:10.2174/0929867324666171003114154.
   PubMed Web of Science ®Google Scholar
• Md Shahazul Islam, Cristina Quispe, Rajib Hossain, Muhammad Torequl Islam, Ahmed Al-Harrasi, Ahmed Al-Rawahi, Miquel Martorell, Assem Mamurova, Ainur Seilkhan, Nazgul Altybaeva, et al., “Neuropharmacological Effects of Quercetin: A Literature-Based Review,” Frontiers in Pharmacology 12 (2021): 665031. doi:10.3389/fphar.2021.665031.
   PubMed Web of Science ®Google Scholar
• “Schrodinger. Schrodinger Release 2020-4.” https://www.schrodinger.com.
   Google Scholar
• O. Gerlits, K.Y. Ho, X. Cheng, D. Blumenthal, P. Taylor, A. Kovalevsky, and Z. Radic, “A New Crystal Form of Human Acetylcholinesterase for Exploratory Room-Temperature Crystallography Studies,” Chemico-Biological Interactions 25, no. 309 (2019): 108698. doi:10.1016/j.cbi.2019.06.011.
   Google Scholar
• C. Binda, J. Wang, L. Pisani, C. Caccia, A. Carotti, P. Salvati, D.E. Edmondson, and A. Mattevi, “Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: safinamide and Coumarin Analogs,” Journal of Medicinal Chemistry 50, no. 23 (2007): 5848–52. doi:10.1021/jm070677y.
   PubMed Web of Science ®Google Scholar